Video

Dr. Brody on the Expanding Role of Venetoclax in MCL

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Joshua Brody, MD, director of the Lymphoma program at Icahn School of Medicine, Mount Sinai Hospital, discusses the expanding role of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Venetoclax, a BCL-2 inhibitor, as a single agent or in combination with obinutuzumab (Gazyva) currently has FDA approvals in chronic lymphocytic leukemia and acute myeloid leukemia, says Brody. In MCL, venetoclax appears to be a promising emerging agent for patients with BTK inhibitor–refractory and –naïve disease.

Data with venetoclax have shown high overall and complete response rates with durable remissions in patients with MCL, Brody says. Additionally, the toxicity profile of venetoclax in MCL appears similar to what has been observed in CLL, explains Brody. Regarding safety, venetoclax poses an early risk of tumor lysis syndrome; however, the risk appears to be manageable with standard dose titration.


Overall, it is difficult to predict which B-cell malignancies venetoclax will have activity in, says Brody. However, as BCL-2 is widely expressed in MCL, there is rationale to evaluate the agent in this space, concludes Brody.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity